Business Wire

FDNA Launches Genomics Collaborative® with Multiple Research Partners Globally.

Del

FDNA (www.fdna.com) today announces the launch of the Genomics Collaborative (www.GenomicsCollaborative.com) along with multiple medical research collaborations as part of a new global initiative. Collaborators are using FDNA’s artificial intelligence and deep learning technologies to develop new precision medicine approaches for diagnosing and treating disease, and improving patients’ quality of life.

As a part of the announcement, FDNA is holding an open call for collaboration with patient advocacy groups, clinicians, labs and life sciences stakeholders.

Projects in the Genomics Collaborative are focused on using computational techniques that integrate phenotypic data into the analysis of human genetics. This process, known as “next-generation phenotyping,” or NGP, captures, structures and interprets complex physiological information.

This NGP-generated data can then be used to interpret patient genomic data to help recognize current and future health risks, as well as identify therapeutic targets that will maximize quality and length of life.

To accomplish these goals, FDNA has offered collaborators access to its technologies, which use deep learning neural networks to de-identify and analyze patients’ phenotypic information captured in images, clinical notes, and voice and video recordings to discover correlations between patient data and disease.

As part of the Genomics Collaborative launch, multiple collaborators are announcing projects and support.

Greenwood Genetic Center (GGC) in Greenwood, South Carolina has announced plans to evaluate the use of NGP in identifying and recognizing relationships between certain biomarkers and disease. One planned exploration is of the potential to correlate patterns of facial features with metabolite profiles for various genetic syndromes.

"GGC looks forward to developing new approaches to understanding our patients' health through analysis of metabolites and related genomic data," said Dr. Steve Skinner, Director of GGC. "FDNA's next-generation phenotyping technologies will support GGC in this through advanced capture and analysis of the phenotype, and use of that data to understand the patient's genome as it relates to diagnosis and care."

Dr. Andrea Superti-Furga, Head of Genetic Medicine at Lausanne University Hospital in Switzerland, is working with FDNA in the Genomics Collaborative to analyze correlations between bone structure and genomic data in hopes of yielding discoveries that will support earlier recognition and intervention for patients with skeletal dysplasia disorders.

“We are excited to analyze the characteristics of bone shape and growth for patients affected by one of the more than 400 distinct skeletal dysplasia disorders,” said Superti-Furga. “Next-generation phenotyping technologies have potential to help clinicians recognize underlying genetic or developmental problems earlier in life, allowing for more rapid diagnosis, personalized intervention and improved quality of life.”

Dr. William Dobyns at Seattle Children’s Hospital is contributing clinical data on brain abnormalities to help FDNA determine if such data correlates to genetic variations.

“FDNA has a track record of developing helpful solutions that make a real impact on patient lives,” said Dobyns, who is a medical geneticist and a pediatric neurologist. “I am pleased to help continue that tradition through contributing this data to the Genomics Collaborative.”

Bridge the Gap, an advocacy group in Cypress, Texas, is working with patients, clinicians and FDNA to study SYNGAP1 gene variants related to Fragile X, Angelman, and other related syndromes. The project aims to advance the use of facial analysis and other NGP approaches to help clinicians provide diagnosis and early personalized intervention.

The advocacy group All Things Kabuki is announcing a project to increase recognition of the Kabuki syndrome phenotype and its related gene variants. This will include facial analysis studies to enhance the capabilities already known within Face2Gene.

The successful launch of the Genomics Collaborative is credited to numerous partners, including FDNA’s Centers of Excellence in Research, which began projects with FDNA in 2017 and will continue as part of the Genomics Collaborative.

Current progress can be seen at www.GenomicsCollaborative.com.

“The patient is our greatest asset for the future of precision medicine,” said Ilana Jacqueline, Coordinator of the Genomics Collaborative and Manager of Patient Advocacy for FDNA. “The Genomics Collaborative is making it possible to look at patients in a safe, secure way to help understand how doctors can better diagnose and treat patients, based on their unique traits.”

“We’re interested in working with others to develop technologies that easily capture and analyze that data to help health care providers have all the facts when they are evaluating patients,” Jacqueline continued, “When it comes to having the means to make a faster and more accurate diagnosis, physicians should have every advantage.”

FDNA will work with collaborators to design specific studies and securely capture and analyze patient health data that relates to the proposed research hypotheses. Data will be collected using secure portals and patient questionnaires, when applicable. Collaborators can gather and analyze a variety of data relating to the patient’s symptoms, signs, lifestyle, medical history, and genetic data.

Interested advocacy groups, clinicians, patients and researchers can visit www.genomicscollaborative.com for more information.

About the FDNA Genomics Collaborative

The Genomics Collaborative is an FDNA initiative to accelerate breakthrough in precision medicine using deep learning and artificial intelligence (AI).

Collaborators are using FDNA’s next-generation phenotyping (NGP) technologies, to analyze patient clinical data and next-generation sequencing (NGS) data. The result will be real-time discovery of disease biomarkers, advancement of clinical and molecular technologies, and big genomic data that will increase the ability of genetic testing to provide meaningful answers to difficult health questions.

About Face2Gene and FDNA

FDNA is the developer of Face2Gene* ( www.Face2gene.com ), a suite of phenotyping applications that facilitates comprehensive and precise genetic evaluations. FDNA uses artificial intelligence to detect physiological patterns that reveal disease-causing genetic variations. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases, FDNA is changing the game for precision medicine.

*Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.

Contact information

FDNA
Ilana Jacqueline
ilana@fdna.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs